COVID-19 Vaccine Competitors Divest Financial Holdings

England-based AstraZeneca plc disclosed it recorded $1.38 billion in equity portfolio sales in 2020, with "a large proportion" of cash coming from the sales of Massachusetts-based Moderna Inc. sale, according to the company's recent annual report.

AstraZeneca and Moderna are rivals in the very competitive COVID-19 vaccine market segment.

Previously, Merck disclosed it too sold shares on Moderna in December 2020.